Blis Technologies Limited · NZX:BLT
Blis Technologies — Shareholder Meeting (July 2021)
41 slides from Blis Technologies's shareholder meeting presentation, Jul 21, 2021
Slide 1: 2021 Annual Shareholder Meeting
2021 ANNUAL SHAREHOLDER MEETING 21 July 2021
Slide 2: Attendees Question and Voting Process
Attendees Question and Voting Process. The voting box Question box
Slide 3: Meeting Agenda
Meeting Agenda. Business of the Meeting Chairperson’s Address • Tony Offen Chief Executive Officer’s Address • Brian Watson Ordinary Resolutions • Re-election of Geoff Plunket as a director • Re-election of Barry Richardson as a director • Directors authorised to fix the auditors remuneration Other
Slide 4: Board of Directors
Board of Directors. Anthony (Tony) Offen Geoffrey Plunket Dr Alison Stewart Chair, Independent Independent non-executive director Independent non-executive director non-executive director Chair of Audit and Risk Committee Chair of Remuneration Committee Antony (Tony) Balfour Dr Barry Richardson Inde
Slide 5: Disclaimer
Disclaimer. In making an investment decision, investors must rely involve significant elements of subjective judgement Information on their own examination of the Company, including the and assumptions as to future events which may or may The information in this presentation is an overview and merit
Slide 6: Results FY 21
Results FY 21. Revenue (NZ$m) EBITDA (NZ$m) $12.0 $4.0 10.6m $ 10.6m $ $9.0 8.2m $ 2.1m $ $2.0 6.5m $ 1.0m $ 0.9m $ $6.0 5.3m $ 0.6m $ $ $3.0 0.4m -$ $ -$2.0 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21
Slide 7: Probi
CONFIDENTIAL CONFIDENTIAL bi Probi Probi. July, 2021 July, 2021
Slide 8: CEO Address
CEO Address. Brian Watson Chief Executive Officer (CEO)
Slide 9: The BLIS Leadership Team
The BLIS Leadership Team. Brian Watson Richard Wingham Julie Curphey Chief Executive Officer (CEO) Chief Financial Officer (CFO) Chief Marketing Officer (CMO) Dr John Hale Frank Spiewack Laura Grant Chief Technology Officer (CTO) Commercial Director e-Commerce Director
Slide 10: FY21 summary
FY21 summary. Revenue (NZ$m) EBITDA (NZ$m) FY21 Revenue (NZ$m) $12.0 $4.0 10.6m $ 10.6m $ $ 3.2m $9.0 2.1m $ 5.1m 8.2m $ $ $2.0 6.5m $ 1.0m $ 0.9m $ 2.4m $ $6.0 5.3m $ 0.6m $ $ $3.0 0.4m -$ $ -$2.0 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 Asia Pacific Europe, Middle East, Africa FY Revenue
Slide 11: FY21 summary
FY21 summary. New market New probiotic strain and new Regulatory approvals Capability build and key new hires developments: product launch » Finalised Health Canada » E-commerce, Marketing, Sales » Canada launch » Commercial release of BLIS approvals for BLIS® finished » CBEC Tmall Flagship Q24™ pro
Slide 12: Q1 update
Q1 update. Unaudited results for the quarter ending 30 June 2021 (Q1 FY22) Revenue and EBITDA are in-line with our expectations $ 1.8m Total revenue for the quarter $ 1.2m EBITDA loss Outlook. » We remain confident of delivering revenue growth in the current financial year » Meaningful longer-term g
Slide 13: Our purpose
Our purpose. Core branded Innovation revenue streams through R&D Developing breakthrough probiotic solutions for the health and wellbeing of global consumers.
Slide 14: Strategic focus and growth agenda
Strategic focus and growth agenda. Strategic priorities: Build our branded finished product e-commerce sales presence. » Priority markets: Australasia, USA, China Cross-Border e-commerce (CBEC), Canada » Supported by retail in NZ, Australia, Canada Three health and wellness targets » ENT/ Immunity »
Slide 15: Addressable markets
Addressable markets. Global Probiotic Supplements Market Revenue $8.0 $7.5 +12% COSMETIC $7.0 +8% SKINCARE $6.5 • Global premium skincare market was +7 % valued at US$140 billion in 20191 $6.0 • Global “microbiome modulators” skincare market was valued at $5.5 US$0.5 billion market in 2019 and is a
Slide 16: Probi strategic partnership
Probi strategic partnership. Additional growth pathway Establishment of a licence and supply agreement to drive increased revenue » Blis grants Probi the right to manufacture and sell BLIS K12™, BLIS M18™ as ingredients and finished products and the opportunity to collaborate on future products. Col
Slide 17: Probi in brief
Probi in brief Probi AB is a Swedish listed biotechnology company. One of the largest, leading probiotic companies in the world Our vision Probi was founded by researchers in Lund in 1991. Probi aspires to be the innova- Today we are one of the largest and leading global tive frontrunner within pro-
Slide 18: A leading global probiotic company
A leading global probiotic company LUND 176 REDMOND Head office, R&D Fermentation At the end of 2020 Probi had 176 employees. SINGAPORE LAFAYETTE Sales office Manufacturing >40 and packaging Probis products are sold in i over 40 countries and more countries are contin- ually being added. Americas EM
Slide 19: Probi: A word from Probi CEO
CONFIDENTIAL CONFIDENTIAL bi Probi Probi. A word from Probi CEO, July, 2021 Tom Rönnlund
Slide 20: Scope of collaboration – delivering significant value
Scope of collaboration – delivering significant value. Primary opportunities: Broader opportunities: • R&D – shared expertise to develop innovative probiotic solutions • Scientific and clinical validation of probiotic health benefits Blis Probi • Contract manufacture – both fermentation » Substantia
Slide 21: Use of the capital funds
Use of the capital funds. Accelerate our Pipeline investment Internal capability growth priorities investment • New product development • Skincare launch activity acceleration. • Marketing and e-commerce • New strain development focus • D2C e-commerce investment: USA, CBEC, Australasia, Canada • Can
Slide 22: New market and product initiatives
New market and product initiatives. SKINCARE CANADA CBEC
Slide 23: Skincare product launch
Skincare product Unconditional y Skincare Co. la U nch. Vv Skin peace for all £ BLIS seins
Slide 24: Breakthrough innovation
Breakthrough innovation. Blis’ Addressable Market: From the Skin for the Skin Premium Skincare The unique patented probiotic originates from the skin microbiome so colonises Competitive advantage: harmoniously with your skin Breakthrough innovation No nasty chemicals, no animal testing – The skincar
Slide 25: Influencer engagement
ITEM ID: 1462885573 01 JUL, 2021 HYDRATION HEROES Influencer Remix, New Zealand engagement. Page 1 of 1 PMCA licensed copy. You may not further copy, reproduce, record, retransmit, sell, publish, distribute, share or store this information without
Slide 26: Customer reviews
ITEM ID: 1467514583 05 JUL, 2021 Skincare superstars Customer reviews. Woman (NZ), Auckland Page 1 of 2 Beauty Editor AMY HOULIHAN Skincare superstars These new saviour products don’t just pamper and nourish, they put in the work to treat, strengthen and drastically improve your skin. As good as the
Slide 27: Canada
Canada. Represents an important new market with significant and attractive claim opportunities Omni channel focus • e-commerce sales activity • Retail sales activity with Purity Life
Slide 28: CBEC
CBEC. BLIS PROBIOTICS™ Tmall Flagship store launched Jan 2021 Heavy focus on building our brand presence through digital marketing social media and influencer activity Reseller / Daigou activity remains a contributor but not a primary focus based on challenges in this segment
Slide 29: R&D and NPD pipeline investment
R&D and NPD pipeline investment. NPD New IP generated • Dental: Late-stage probiotic toothpaste development Probi collaboration • Skincare: Additional skincare and personal care targets • Combining innovation strengths • ENT/ Immunity: Kids focus • Extended use of Blis strains • Blis range extension
Slide 30: People and Performance
People and Performance. Key new hires Process • Refreshed company values • Execution focus - Faster and Smarter e-commerce Category Manager Category Global Ingredients Director ENT/ Immunity Manager Skin and Private Label Account Manager • Sustainability focus • Digital strategy and knowledge manage
Slide 31: Sustainability
Sustainability. Our Sustainability priorities are linked to the UN Sustainability Goals • Access products Advance Health • Focus on quality & Wellbeing • Staff wellbeing Contribution to • Economic contribution • Support of charities and sponsorship Society • Staff policies: living wage, diversity, d
Slide 32: Green lab certification
Green lab certification. Blis is proud to be the first NZ based lab to complete this international certification achieving the highest level of certification. Topics Covered Our green lab certification program covers 14 topics related to energy, water, waste, chemistry/materials and engagement. Cong
Slide 33: Summary
Summary. ATTRACTIVE TRACK LONG TERM ADDRESSABLE CLEAR RECORD OF STRATEGIC GLOBAL GROWTH PROBIOTIC PARTNERSHIP MARKETS PRIORITIES INNOVATION FOR GROWTH
Slide 34: Questions
Questions. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 35: Attendees Question Process
Attendees Question Process. The voting box Question box
Slide 36: Resolutions
Resolutions. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 37: Attendees Voting Process
Attendees Voting Process. The voting box Question box
Slide 38: Resolution 1
Resolution 1. That Mr Geoffrey Plunket be elected as a director of the Company. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 39: Resolution 2
Resolution 2. That Dr Barry Richardson be elected as a director of the Company. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 40: Resolution 3
Resolution 3. That the Directors be authorised to fix the remuneration of the auditors for the ensuing year. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 41: General Business
General Business. i. B LIS Technologies